Biosimilars of low molecular weight heparins (LMWHs) are more alike the originator than
different branded LMWHs. The latter differ largely in molecular weight, anti‐FXa/anti‐FIIa …

Biosimilar low‐molecular‐weight heparins (LMWHs) have been produced in the past years
and are currently being marketed in China, India, Argentina and Brasil. The United States …

A working group of clinicians and scientists was formed to review the clinical considerations
for use of low‐molecular‐weight heparin (LMWH) biosimilars. LMWH are biological …

Based on the results of large clinical trials, several low‐molecular‐weight heparins (LMWHs)
have been approved for prophylaxis and the treatment of venous and arterial …

Abstract Recently, the European Medicines Agency (EMA) authorized the introduction and
marketing of Thorinane® and Inhixa®, biosimilars of the Low Molecular Weight Heparin …

Low molecular weight heparins (LMWHs) were first introduced into clinical use in the mid-
1980s, and are now among the therapeutics of choice for the prevention and treatment of …

Generic drugs are an important component for meaningful health-care reform currently
being debated in the United States. Aside from defining the period of drug exclusivity …

The protection rights of low molecular weight heparins (LMWHs) are expired or are expiring,
so the extent and nature of the studies required to obtain a market authorization for LMWH …

This article examines the market entry of biosimilar low-molecular-weight heparins (LMWHs)
in Europe by focusing on regulatory requirements, pricing, reimbursement, prescribing, and …

The development of biosimilar versions of low molecular weight heparins (LMWHs) raises
real medical concerns. To illustrate this, we have chosen as an example the specific clinical …